Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Approvals & launches

Renaissance Pharma's daretabart secures FDA Breakthrough status in paediatric neuroblastoma

Essential Pharma's Renaissance Pharma unit has won a US regulatory designation for its anti-GD2 antibody in frontline high-risk childhood cancer, though the drug has no marketing clearance anywhere.

16 Nov 2026 · Essential Pharma · Company news

Renaissance Pharma, part of Essential Pharma, has added a regulatory milestone to its paediatric oncology pipeline. On 16 November 2026 the company said the US Food and Drug Administration had given daretabart, an anti-GD2 antibody, Breakthrough Therapy Designation. The label applies to the antibody combined with induction chemotherapy as initial treatment for children whose high-risk neuroblastoma has just been diagnosed.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Approvals & launchesAll →